Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels.
作者信息
Lujan Juliana Velez, Lengerke-Diaz Paula A, Jacobs Chaja, Moreno-Cortes Eider F, Ramirez-Segura Cesar A, Choi Michael Y, McCarthy Colin, Heinen Alaina, Kipps Thomas J, Castro Januario E
机构信息
UC San Diego Moores Cancer Center, San Diego, CA.
Mayo Clinic, Scottsdale, AZ, USA.
出版信息
Haematologica. 2020 Jan;105(1):e22-e25. doi: 10.3324/haematol.2018.212597. Epub 2019 May 2.
Abstract
摘要
相似文献
1
Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels.伊布替尼可降低慢性淋巴细胞白血病患者中奥滨尤妥珠单抗输注相关反应，并与血浆细胞因子水平变化相关。
Haematologica. 2020 Jan;105(1):e22-e25. doi: 10.3324/haematol.2018.212597. Epub 2019 May 2.
2
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.依鲁替尼预处理可减少细胞因子分泌，并降低慢性淋巴细胞白血病患者中奥滨尤妥珠单抗诱导的输注相关反应风险：来自iLLUMINATE研究的分析
Ann Hematol. 2021 Jul;100(7):1733-1742. doi: 10.1007/s00277-021-04536-6. Epub 2021 May 20.
3
Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial.苯达莫司汀、奥滨尤妥珠单抗（GA101）和伊布替尼序贯治疗慢性淋巴细胞白血病（CLL）：CLL2 - BIG试验的最终结果
Leukemia. 2022 Aug;36(8):2125-2128. doi: 10.1038/s41375-022-01629-7. Epub 2022 Jun 25.
4
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.奥妥珠单抗联合伊布替尼诱导治疗，随后采用微小残留病驱动策略治疗慢性淋巴细胞白血病患者（ICLL07 FILO）：一项单臂、多中心、2期试验。
Lancet Haematol. 2019 Sep;6(9):e470-e479. doi: 10.1016/S2352-3026(19)30113-9. Epub 2019 Jul 16.
5
A cross-trial comparison of single-agent ibrutinib chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.在既往未经治疗的慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患者中，单药伊布替尼与苯丁酸氮芥-奥滨尤妥珠单抗的跨试验比较。
Haematologica. 2020 Apr;105(4):e164-e168. doi: 10.3324/haematol.2019.223743. Epub 2019 Aug 14.
6
[Current diagnosis and treatment of chronic lymphocytic leukaemia].[慢性淋巴细胞白血病的当前诊断与治疗]
Dtsch Med Wochenschr. 2020 Aug;145(16):1139-1144. doi: 10.1055/a-1039-8472. Epub 2020 Aug 13.
7
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.伊布替尼联合奥滨尤妥珠单抗与苯丁酸氮芥联合奥滨尤妥珠单抗一线治疗慢性淋巴细胞白血病（ILLUMINATE）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3.
8
Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis.阿卡拉布替尼联合奥滨尤妥珠单抗、伊布替尼联合奥滨尤妥珠单抗与维奈托克联合奥滨尤妥珠单抗治疗初治 CLL 的比较：一项网络荟萃分析。
Leuk Lymphoma. 2020 Dec;61(14):3432-3439. doi: 10.1080/10428194.2020.1811271. Epub 2020 Aug 30.
9
Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.CD20 抗体和激酶抑制剂对慢性淋巴细胞白血病细胞 B 细胞受体信号转导和存活的影响。
Br J Haematol. 2021 Jan;192(2):333-342. doi: 10.1111/bjh.17139. Epub 2020 Nov 20.
10
[Subendocardial injury with no evidence of atherosclerosis associated with obinutuzumab infusion].[伴有obinutuzumab输注相关的无动脉粥样硬化证据的心内膜下损伤]
Medicina (B Aires). 2021;81(6):1052-1055.
引用本文的文献
1
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.一项在复发或难治性慢性淋巴细胞白血病患者中评估伊布替尼联合奥滨尤妥珠单抗的 1b 期研究。
Leukemia. 2023 Apr;37(4):835-842. doi: 10.1038/s41375-023-01830-2. Epub 2023 Jan 30.
2
Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors.新型策略可减轻 T 细胞参与疗法引起的细胞因子释放综合征，重点是使用激酶抑制剂。
Oncoimmunology. 2022 Jun 1;11(1):2083479. doi: 10.1080/2162402X.2022.2083479. eCollection 2022.
3
COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response.COVID-19 与血液系统恶性肿瘤患者：临床表现、持续性和免疫反应。
Acta Haematol. 2022;145(3):297-309. doi: 10.1159/000523872. Epub 2022 Mar 2.
4
Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia.真实世界中奥滨尤妥珠单抗联合苯丁酸氮芥输注反应的风险，以及与其他慢性淋巴细胞白血病一线治疗相比的有效性。
BMC Cancer. 2022 Feb 6;22(1):148. doi: 10.1186/s12885-022-09256-2.
5
Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576.伊布替尼联合奥滨尤妥珠单抗作为慢性淋巴细胞白血病的一线治疗与较低的输液相关反应发生率以及伊布替尼停药后持续缓解相关：一项单臂、开放标签的1b/2期临床试验（NCT0231576）
Adv Hematol. 2022 Jan 22;2022:4450824. doi: 10.1155/2022/4450824. eCollection 2022.
6
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.依鲁替尼预处理可减少细胞因子分泌，并降低慢性淋巴细胞白血病患者中奥滨尤妥珠单抗诱导的输注相关反应风险：来自iLLUMINATE研究的分析
Ann Hematol. 2021 Jul;100(7):1733-1742. doi: 10.1007/s00277-021-04536-6. Epub 2021 May 20.
7
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma.泽布替尼（BGB-3111）联合奥妥珠单抗治疗慢性淋巴细胞白血病和滤泡性淋巴瘤患者。
Blood Adv. 2020 Oct 13;4(19):4802-4811. doi: 10.1182/bloodadvances.2020002183.
8
Clinical application of obinutuzumab for treating chronic lymphocytic leukemia.奥妥珠单抗治疗慢性淋巴细胞白血病的临床应用
Drug Des Devel Ther. 2019 Aug 19;13:2899-2909. doi: 10.2147/DDDT.S212500. eCollection 2019.
本文引用的文献
1
Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.在 IIIb 期 GREEN 研究中，奥滨尤妥珠单抗单药或联合化疗治疗未经治疗或复发/难治性慢性淋巴细胞白血病的安全性。
Haematologica. 2018 Nov;103(11):1889-1898. doi: 10.3324/haematol.2017.186387. Epub 2018 Jul 5.
2
A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.新型II型抗CD20单克隆抗体奥滨尤妥珠单抗（GA101）治疗B细胞恶性肿瘤患者的综述
Adv Ther. 2017 Feb;34(2):324-356. doi: 10.1007/s12325-016-0451-1. Epub 2016 Dec 21.
3
Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain.奥妥珠单抗联合苯丁酸氮芥用于西班牙慢性淋巴细胞白血病患者一线治疗的经济学评估
Clinicoecon Outcomes Res. 2016 Sep 21;8:475-484. doi: 10.2147/CEOR.S114524. eCollection 2016.
4
Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.激酶抑制剂依鲁替尼用于预防抗CD19嵌合抗原受体T细胞治疗B细胞肿瘤后发生的细胞因子释放综合征。
Leukemia. 2017 Jan;31(1):246-248. doi: 10.1038/leu.2016.262. Epub 2016 Sep 28.
5
Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.当全剂量氟达拉滨不适用时一线慢性淋巴细胞白血病治疗的成本效益
Clin Ther. 2016 Apr;38(4):889-904.e14. doi: 10.1016/j.clinthera.2016.02.005. Epub 2016 Mar 10.
6
Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.奥妥珠单抗单药治疗有症状的初治慢性淋巴细胞白血病的随机2期研究。
Blood. 2016 Jan 7;127(1):79-86. doi: 10.1182/blood-2015-03-634394. Epub 2015 Oct 15.
7
Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.接受奥滨尤妥珠单抗治疗的慢性淋巴细胞白血病患者的细胞因子释放及其与输注相关反应的可能关系。
Blood. 2015 Dec 10;126(24):2646-9. doi: 10.1182/blood-2015-09-670802. Epub 2015 Oct 7.
8
Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.奥滨尤妥珠单抗联合氟达拉滨/环磷酰胺或苯达莫司汀用于慢性淋巴细胞白血病患者的初始治疗：1b期GALTON试验
Blood. 2015 Apr 30;125(18):2779-85. doi: 10.1182/blood-2014-12-613570. Epub 2015 Mar 13.
9
Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: results from a Swedish national observational study.在临床实践中，严重的输液相关反应在接受利妥昔单抗治疗的慢性淋巴细胞白血病（CLL）患者中并不常见：一项瑞典全国性观察性研究的结果
Leuk Res. 2015 Jan;39(1):33-7. doi: 10.1016/j.leukres.2014.09.019. Epub 2014 Nov 13.
10
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.奥滨尤妥珠单抗联合苯丁酸氮芥治疗伴有合并症的 CLL 患者。
N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8.
Zotero 插件